1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Three annual review cycles: deadlines December 1, April 30, and August 31. Next upcoming deadline is August 31 (review in December).
Elsa U. Pardee Foundation Cancer Research Grants is a program from the Elsa U. Pardee Foundation that funds early-stage cancer research aimed at identifying new treatments or cures for cancer at U.S. nonprofit institutions.
The program supports one-year projects designed to establish new capabilities for emerging cancer researchers or to allow established researchers to explore novel approaches, with the expectation that seed funding will lead to expanded government or private support. Three application cycles are offered each year with deadlines of December 1, April 30, and August 31.
Eligible applicants are principal investigators at U.S. nonprofit research institutions.
Get alerted about grants like this
Save a search for “Elsa U. Pardee Foundation” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
How To Apply - The Elsa U. Pardee Foundation This website has been built to accept online applications for grants from the Elsa U. Pardee Foundation.
Once you gather your information, you will be able to proceed to the proposal form. You may submit your application at one time or return to edit information later. However, once you submit your application, it can no longer be changed or updated.
You can view a sample application here. There are three application cycles each year. Application Deadline Final Review December 1 May April 30 September August 31 December Confirmation that your grant request has been successfully submitted will be generated from the application system as soon as you submit your application.
There will be no additional confirmation sent via email or other communication medium. The Principal Investigator will be notified via email of the final decision on the grant request. We do not provide reviewer feedback/comments.
The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers.
It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified. By design, there are no limits set on the grant amount that can be requested.
It must be reasonable and clearly supported by the scope of the project outlined in the application. Applications requesting more than 5% overhead are usually not considered. Papers verifying nonprofit status and relevant human subject and experimental animal treatment approvals from the recipient institution will be requested prior to project initiation.
A final report summarizing financial expenditure and research achievement is required. To view our FAQs, please click here. General/Contact Information consists of the name of the Principal Investigator (PI), PI title, your recipient institution, project title, project duration/timeline, project cost, project summary, and PI and institution contact addresses.
The project summary (1700 characters maximum) of the grant application should summarize the project hypothesis, goals, and experimental methods to be employed. Relevance of the project to cancer treatment and cure should be included. Experimental Approach or Project Plan (Text only, unformatted, no images, characters or symbols) Project Plan (maximum 20,000 characters).
This section should provide a project introduction, define project principle aims, and define project experimental approaches in text form. References should be entered using the suggested format in the application. Preliminary Results (May include images, .
PDF format) Preliminary results (two page maximum). Experimental results providing data supporting the application should be included. Graphs and pictures may be included in PDF format.
Personnel are known individuals who would be receiving compensation for work toward the project. This page provides space for a brief CV of the PI. Additional pages should be used for coPI’s and research associates.
Budget information should include a personnel section detailing salary, fringes, percent effort on this grant, and calculated amounts requested for PI, coPI ’s and supporting personnel. Supplies and other items should be separately listed. Justification of the budget is also requested.
Overhead is limited to 5%. Essential equipment cannot exceed $5000. Current and Pending Grants The list of pending and active grants for the PI/co-PI, and all key personnel (e.g., Research Associate, Consultants, etc.) should include Title, Role, Grantor, grant duration, grant amount, time committed by the PI, and the extent of overlap with this Pardee grant application.
Additionally, the original Abstract for each currently funded and pending grant must be provided. Failure to provide this information will result in your application being removed from the review process. Verification of institution nonprofit status will be requested and must be provided following grant application approval for funding.
Human subjects and experimental animal institutional approvals will be requested and must be provided if applicable, following grant application approval for funding. If multiple grants with substantial overlap are awarded, the expectation is the PI will accept only one funding source. Start an Application to Begin Your Proposal Or Login to Check The Progress In order to begin your grant proposal, you must create an account and apply .
After your account is created and started an application, you can login to review your submission. The Principal Investigator will be notified by email of the official grant results.
Key questions and narrative sections extracted from the solicitation.
Project summary (1,700 characters maximum)
Experimental approach (20,000 characters maximum)
References
Preliminary results (2-page maximum)
Personnel information
Budget justification
Documentation of current/pending grants with abstracts
Based on current listing details, eligibility includes: Researchers at U.S. non-profit institutions; projects must target identifying new treatments or cures for cancer; one-year funding period. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Generally $80,000 to $190,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is August 31, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.